Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-14074.95%
operating margin TTM
-12191.11%
revenue TTM
22.39 Million
revenue per share TTM
0.59$
valuation ratios | |
|---|---|
| pe ratio | -20.07 |
| peg ratio | -0.20 |
| price to book ratio | -95.29 |
| price to sales ratio | 2,963.20 |
| enterprise value multiple | -24.12 |
| price fair value | -95.29 |
profitability ratios | |
|---|---|
| gross profit margin | 100.0% |
| operating profit margin | -12191.11% |
| pretax profit margin | -14076.08% |
| net profit margin | -14074.95% |
| return on assets | -60.62% |
| return on equity | 47.21% |
| return on capital employed | -59.31% |
liquidity ratio | |
|---|---|
| current ratio | 6.75 |
| quick ratio | 6.75 |
| cash ratio | 0.72 |
efficiency ratio | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 0.00 |
| days of payables outstanding | 0.00 |
| cash conversion cycle | 0.00 |
| receivables turnover | 0.00 |
| payables turnover | 0.00 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.23 |
| debt equity ratio | -1.82 |
| long term debt to capitalization | 2.27 |
| total debt to capitalization | 2.22 |
| interest coverage | -6.47 |
| cash flow to debt ratio | -1.71 |
cash flow ratios | |
|---|---|
| free cash flow per share | -5.71 |
| cash per share | 10.67 |
| operating cash flow per share | -5.62 |
| free cash flow operating cash flow ratio | 1.02 |
| cash flow coverage ratios | -1.71 |
| short term coverage ratios | -94.96 |
| capital expenditure coverage ratio | -62.47 |
Frequently Asked Questions
When was the last time Reata Pharmaceuticals, Inc. (NASDAQ:RETA) reported earnings?
Reata Pharmaceuticals, Inc. (RETA) published its most recent earnings results on 08-08-2023.
What is Reata Pharmaceuticals, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Reata Pharmaceuticals, Inc. (NASDAQ:RETA)'s trailing twelve months ROE is 47.21%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Reata Pharmaceuticals, Inc. (RETA) currently has a ROA of -60.62%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did RETA's net profit margin stand at?
RETA reported a profit margin of -14074.95% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is RETA's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 6.75 in the most recent quarter. The quick ratio stood at 6.75, with a Debt/Eq ratio of -1.82.